We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
Toggle Summary TESARO Announces Data Presentations at the 2019 SGO Annual Meeting on Women’s Cancer
WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- TESARO, an oncology-focused business within GSK, today announced that data for dostarlimab (anti-PD-1 antibody, formerly TSR-042) and Zejula® (niraparib) will be presented at the 2019 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s
View HTML
Toggle Summary Actor Scott Foley and TESARO Team Up to Empower Ovarian Cancer Care Partners Through New Phase of Not on My Watch Movement
In a New Public Service Announcement, Foley Reveals for the First Time his Personal Story of Caring for his Mother Following Ovarian Cancer Recurrence WALTHAM, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc., an oncology-focused business within GSK, announced today that acclaimed actor Scott
View HTML
Toggle Summary TESARO, Inc. Provides Notice of Fundamental Change, Conversion Rate Adjustment pursuant to Make-Whole Adjustment Event and Supplemental Indenture
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc. (the “ Company ” or “ TESARO ”), an oncology-focused biopharmaceutical company, today announced that pursuant to the terms of the Indenture and the First Supplemental Indenture to the Indenture (collectively, the “ Indenture ”)
View HTML
Toggle Summary GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
Toggle Summary TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes
WALTHAM, Mass. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that, pursuant to the terms of the indenture (the “Indenture”) governing the terms of its 3.00% Convertible Senior notes due 2021 (the “Notes”), it
View HTML
Toggle Summary GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham,
View HTML
Toggle Summary TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatment TSR-042 monotherapy demonstrated significant activity in patients with previously treated recurrent/advanced
View HTML
Toggle Summary TESARO Announces Third-Quarter 2018 Operating Results
ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017 Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients regardless of BRCA mutation status anticipated in late 2019 Data presented at ESMO for TSR-042 indicate robust activity in
View HTML
Toggle Summary The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year
CHICAGO and WALTHAM, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), and TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the third year of their
View HTML